This site is for health care professionals only.

@ ESMO Virtual Congress 2020

 

Reimagining Medicine: Helping to Improve the Lives of Patients With Melanoma

Melanoma Disease Education Library

Brightly color chameleon next to a camouflaged chameleon with text: BRAF+ melanoma: What makes it different makes it vulnerable

BRAF+ Melanoma: What Makes It Different Makes It Vulnerable

Learn more about BRAF mutation and its role in melanoma, the rationale for BRAF-mutation testing and treatment with BRAF inhibitors, the procedures for BRAF-mutation testing, and the testing methods that are available.

Learn More

Melanoma Exhibit

Melanoma Revealed Exhibit

Learn more about the science and art behind the exhibition and explore the Instagram below

Clinical Trials

LXH254 + Spartalizumab in MAPK-altered solid tumors TIP
PLATforM
LXH254 Combinations in BRAF V600 or NRAS-Mutant Melanoma

Compound Cards

PD-1 monoclonal antibody: Spartalizumab (PDR001)
IL-1β antibody: Canakinumab (ACZ885)
MET inhibitor: Capmatinib (INC280)
PD-1 monoclonal antibody + Adenosine 2A receptor antagonist: Spartalizumab (PDR001) + NIR178
PD-1 + TIM-3 monoclonal antibodies: Spartalizumab (PDR001) + MBG453
RAF inhibitor: LXH254
ERK inhibitor: LTT462
IL-15 Agonist: NIZ985
All compounds are either investigational or being studied for (a) new uses(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.